Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nanopore sequencing of 1000 Genomes Project samples to build a comprehensive catalog of human genetic variation.
Gustafson JA, Gibson SB, Damaraju N, Zalusky MP, Hoekzema K, Twesigomwe D, Yang L, Snead AA, Richmond PA, De Coster W, Olson ND, Guarracino A, Li Q, Miller AL, Goffena J, Anderson Z, Storz SH, Ward SA, Sinha M, Gonzaga-Jauregui C, Clarke WE, Basile AO, Corvelo A, Reeves C, Helland A, Musunuri RL, Revsine M, Patterson KE, Paschal CR, Zakarian C, Goodwin S, Jensen TD, Robb E; 1000 Genomes ONT Sequencing Consortium; University of Washington Center for Rare Disease Research (UW-CRDR); Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) Consortium; McCombie WR, Sedlazeck FJ, Zook JM, Montgomery SB, Garrison E, Kolmogorov M, Schatz MC, McLaughlin RN Jr, Dashnow H, Zody MC, Loose M, Jain M, Eichler EE, Miller DE. Gustafson JA, et al. Among authors: helland a. medRxiv [Preprint]. 2024 Mar 7:2024.03.05.24303792. doi: 10.1101/2024.03.05.24303792. medRxiv. 2024. PMID: 38496498 Free PMC article. Preprint.
Severus: accurate detection and characterization of somatic structural variation in tumor genomes using long reads.
Keskus A, Bryant A, Ahmad T, Yoo B, Aganezov S, Goretsky A, Donmez A, Lansdon LA, Rodriguez I, Park J, Liu Y, Cui X, Gardner J, McNulty B, Sacco S, Shetty J, Zhao Y, Tran B, Narzisi G, Helland A, Cook DE, Chang PC, Kolesnikov A, Carroll A, Molloy EK, Pushel I, Guest E, Pastinen T, Shafin K, Miga KH, Malikic S, Day CP, Robine N, Sahinalp C, Dean M, Farooqi MS, Paten B, Kolmogorov M. Keskus A, et al. Among authors: helland a. medRxiv [Preprint]. 2024 Mar 26:2024.03.22.24304756. doi: 10.1101/2024.03.22.24304756. medRxiv. 2024. PMID: 38585974 Free PMC article. Preprint.
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å; InPreD Consortium; IMPRESS-Norway Consortium. Puco K, et al. Among authors: helland a. Acta Oncol. 2024 May 23;63:379-384. doi: 10.2340/1651-226X.2024.28322. Acta Oncol. 2024. PMID: 38779911 Free article.
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H; PRIME-ROSE Consortium and the PCM4EU Consortium. Taskén K, et al. Among authors: helland a. Acta Oncol. 2024 May 23;63:385-391. doi: 10.2340/1651-226X.2024.34791. Acta Oncol. 2024. PMID: 38779910 Free article.
Overcoming barriers in biomarker testing. Letter to the Editor regarding: "ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe", by A. Bayle et al.
García-Foncillas J, Arnold D, Avouac B, Lassen U, Laurent-Puig P, Taieb J, Helland Å, Stenzinger A. García-Foncillas J, et al. Among authors: helland a. Ann Oncol. 2024 May 7:S0923-7534(24)00134-0. doi: 10.1016/j.annonc.2024.04.008. Online ahead of print. Ann Oncol. 2024. PMID: 38723866 No abstract available.
Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends.
Nilssen Y, Brustugun OT, Fjellbirkeland L, Grønberg BH, Haram PM, Helbekkmo N, Helland Å, Wahl SGF, Aanerud M, Solberg S. Nilssen Y, et al. Among authors: helland a. Clin Lung Cancer. 2024 Apr 10:S1525-7304(24)00046-9. doi: 10.1016/j.cllc.2024.04.002. Online ahead of print. Clin Lung Cancer. 2024. PMID: 38692990 Free article.
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.
Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A. Miceli R, et al. Among authors: helland a. Acta Oncol. 2024 Apr 21;63:213-219. doi: 10.2340/1651-226X.2024.24179. Acta Oncol. 2024. PMID: 38647024 Free article.
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.
Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å. Haakensen VD, et al. Among authors: helland a. Eur J Cancer. 2024 May;202:113973. doi: 10.1016/j.ejca.2024.113973. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38447379 Free article. Clinical Trial.
276 results